SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-17-067690
Filing Date
2017-03-02
Accepted
2017-03-02 16:20:04
Documents
3
Period of Report
2017-03-23
Effectiveness Date
2017-03-02

Document Format Files

Seq Description Document Type Size
1 DEF 14A d352394ddef14a.htm DEF 14A 515791
2 GRAPHIC g352394g37x14.jpg GRAPHIC 47602
3 GRAPHIC g352394pcpg01.jpg GRAPHIC 4069
  Complete submission text file 0001193125-17-067690.txt   588647
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: DEF 14A | Act: 34 | File No.: 001-36830 | Film No.: 17659065
SIC: 2834 Pharmaceutical Preparations